November 18, 2016 - By Marie Mckinney · 0 Comments
The stock of Trovagene New (NASDAQ:TROV) registered a decrease of 0.52% in short interest. TROV’s total short interest was 2.91 million shares in November as published by FINRA. Its down 0.52% from 2.93M shares, reported previously. With 217,700 shares average volume, it will take short sellers 13 days to cover their TROV’s short positions. The short interest to Trovagene New’s float is 12.51%. The stock increased 1.56% or $0.05 during the last trading session, hitting $3.25. TrovaGene Inc (NASDAQ:TROV) has declined 50.68% since April 18, 2016 and is downtrending. It has underperformed by 55.11% the S&P500.
Trovagene, Inc. is a molecular diagnostic company. The company has a market cap of $106.13 million. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. It currently has negative earnings. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Insitutional Activity: The institutional sentiment increased to 1.29 in 2016 Q2. Its up 0.48, from 0.81 in 2016Q1. The ratio improved, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.
Moreover, State Common Retirement Fund has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 22,300 shares. Tiaa Cref Mngmt Ltd Llc accumulated 0% or 138,968 shares. Tci Wealth Inc holds 0.01% or 2,100 shares in its portfolio. Blackrock Advisors Ltd Liability Corporation has 14,553 shares for 0% of their US portfolio. Manufacturers Life Ins The holds 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 1,275 shares. The California-based Blackrock Institutional Tru Com Na has invested 0% in TrovaGene Inc (NASDAQ:TROV). Highlander Cap Lc holds 0.03% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 8,000 shares. Morgan Stanley, a New York-based fund reported 436,469 shares. Tower Ltd Llc (Trc) holds 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 1,063 shares. Schwab Charles Investment Management has 35,347 shares for 0% of their US portfolio. Ladenburg Thalmann Fincl holds 0% or 330 shares in its portfolio. D E Shaw Comm Inc last reported 0% of its portfolio in the stock. Princeton Cap accumulated 69,270 shares or 0.22% of the stock. Kcg Holdings has 0% invested in the company for 15,764 shares. California Pub Employees Retirement Systems accumulated 0% or 77,200 shares.
Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Monday, April 25 by Piper Jaffray. Janney Capital downgraded the shares of TROV in a report on Friday, March 11 to “Neutral” rating. The stock of TrovaGene Inc (NASDAQ:TROV) has “Outperform” rating given on Friday, August 14 by Leerink Swann. As per Tuesday, March 29, the company rating was maintained by Avondale. As per Tuesday, September 15, the company rating was initiated by Cantor Fitzgerald. Cantor Fitzgerald downgraded it to “Hold” rating and $5 target price in Monday, April 25 report. Leerink Swann downgraded the stock to “Sector Perform” rating in Tuesday, April 26 report.
Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.
More important recent TrovaGene Inc (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office …” on November 07, 2016, also Prnewswire.com published article titled: “Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference”, Zacks.com published: “Why Is Trovagene Inc. (TROV) Stock Soaring Today?” on January 21, 2016. More interesting news about TrovaGene Inc (NASDAQ:TROV) was released by: Prnewswire.com and their article: “Trovagene Schedules Release of Second Quarter 2016 Financial Results and …” with publication date: July 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney